Experimental Hematology
Volume 36, Issue 1 , Pages 1-8 , January 2008

Unmanipulated HLA 2-3 antigen–mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis

  • Hiroyasu Ogawa

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • Corresponding Author InformationOffprint requests to: Hiroyasu Ogawa, M.D., PhD., Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan 663-8501
    • ,
  • Kazuhiro Ikegame

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Katsuji Kaida

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Satoshi Yoshihara

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Tatsuya Fujioka

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Yuki Taniguchi

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Hiroya Tamaki

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Takayuki Inoue

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Hitomi Hasei

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • ,
  • Yasuhiko Iiboshi

      Affiliations

    • First Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Yuko Tazuke

      Affiliations

    • First Department of Surgery, Hyogo College of Medicine, Hyogo, Japan
    • ,
  • Manabu Kawakami

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • ,
  • Eui Ho Kim

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • ,
  • Toshihiro Soma

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • ,
  • Takehiro Inoue

      Affiliations

    • Division of Multidisciplinary Radiotherapy, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    • ,
  • Ichiro Kawase

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan

Received 13 May 2007 ,Revised 30 July 2007 ,Accepted 8 August 2007.

References 

  1. Armitage JO. Medical progress. Bone marrow transplantation. N Engl J Med. 1994;330:827–838
  2. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864–3872
  3. Aversa F, Tabilio F, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193
  4. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–3454
  5. Tabilio A, Falzetti F, Zei T, et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:274–280
  6. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771
  7. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci. 1994;15:221–230
  8. Ogawa H, Soma T, Hosen N, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation. 2002;74:236–243
  9. Ogawa H, Ikegame K, Kawakami M, Taniguchi Y, Oka Y, Kawase I. Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors. Haematologica. 2004;89:373–375
  10. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, et al. Soluble interleukin 2 receptors after bone marrow transplantation. Bone Marrow Transplant. 1990;6:97–101
  11. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation. 1974;18:295–304
  12. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  13. Eizuru Y, Minematsu T, Minamishima Y, et al. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol. 1991;35:1015–1022
  14. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant. 1995;15:247–253
  15. Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant. 2004;33:1143–1150
  16. Ogawa H, Ikegame K, Yoshihara S, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073–1084
  17. Taniguchi Y, Ikegame K, Yoshihara S, Sugiyama H, Kawase I, Ogawa H. Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. Haematologica. 2003;88:ELT06
  18. Yoshihara S, Kato R, Inoue T, et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone HLA–haploidentical nonmyeloablative stem cell transplantation. Transplantation. 2004;77:835–838
  19. Ferrara JL, Levy R, Chao NJ. Pathophysiology mechanism of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347–356
  20. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  21. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283–286
  22. Bacigalupo A, Oneto R, Lamparelli T, et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant. 2001;28:1093–1096
  23. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?. Blood. 1990;76:1037–1045
  24. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329:1225–1230
  25. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073
  26. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  27. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819

PII: S0301-472X(07)00521-8

doi: 10.1016/j.exphem.2007.08.013

Experimental Hematology
Volume 36, Issue 1 , Pages 1-8 , January 2008

Article Tools

* Image Usage & Resolution